NCT04031833View on ClinicalTrials.gov

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

October 24, 2019

Primary Completion Date

November 14, 2022

Study Completion Date

February 15, 2023

Conditions
Cryptococcal Meningitis
Interventions
DRUG

MAT2203

Encochleated amphotericin B

DRUG

Amphotericin B

Intravenous amphotericin B

Trial Locations (1)

Unknown

Infectious Disease Institute, Kampala

All Listed Sponsors
collaborator

University of Minnesota

OTHER

lead

Matinas BioPharma Nanotechnologies, Inc.

INDUSTRY

NCT04031833 - Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) | Biotech Hunter | Biotech Hunter